{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T18:05:06Z","timestamp":1777485906075,"version":"3.51.4"},"reference-count":63,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["J Comput Assist Tomogr"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Treatment strategies for malignant melanoma have rapidly evolved over the past decade. Because of its propensity to develop advanced stage and metastatic disease, melanoma has contributed to the majority of mortalities among patients with skin cancer. The development of novel therapeutics such as immunotherapy and targeted molecular therapies has revolutionized the treatment of patients with advanced stage and metastatic malignant melanoma. Immune checkpoint inhibitors, BRAF\/MEK inhibitors, and other revolutionary therapies have demonstrated remarkable success in the treatment of this common malignancy. Along with these advancements in systemic therapies, imaging has continued to play a critical role in the diagnosis and follow-up of patients with malignant melanoma. As the use of these novel therapies continues to expand, knowledge of the evolving therapeutic landscape of melanoma is becoming critical for radiologists. In this review, we provide a primer for radiologists outlining the evolution of immunotherapy and targeted therapy in the treatment of melanoma. We discuss the critical role of imaging in evaluation of treatment response, including a summary of current imaging response guidelines. Last, we summarize the essential role of imaging in the evaluation of potential adverse events seen in patients with malignant melanoma undergoing treatment with immune checkpoint inhibitors.<\/jats:p>","DOI":"10.1097\/rct.0000000000001315","type":"journal-article","created":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T18:00:27Z","timestamp":1654711227000},"page":"621-632","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["A Decade of Success in Melanoma Immunotherapy and Targeted Therapy: What Every Radiologist Should Know"],"prefix":"10.1097","volume":"46","author":[{"given":"Mark","family":"Chen","sequence":"first","affiliation":[{"name":"Case Western Reserve University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel A.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Radiology, University Hospitals Cleveland Medical Center, Cleveland, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin G.","family":"Yoon","sequence":"additional","affiliation":[{"name":"Case Western Reserve University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek","family":"Vos","sequence":"additional","affiliation":[{"name":"Case Western Reserve University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias G.","family":"Kikano","sequence":"additional","affiliation":[{"name":"Department of Radiology, Brigham & Women's Hospital, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sree Harsha","family":"Tirumani","sequence":"additional","affiliation":[{"name":"Department of Radiology, University Hospitals Cleveland Medical Center, Cleveland, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil H.","family":"Ramaiya","sequence":"additional","affiliation":[{"name":"Department of Radiology, University Hospitals Cleveland Medical Center, Cleveland, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,6,4]]},"reference":[{"key":"bib2-20250802","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1080\/15384047.2019.1640032","article-title":"Current state of melanoma diagnosis and treatment","volume":"20","year":"2019","journal-title":"Cancer Biol Ther"},{"key":"bib3-20250802","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1586\/17469872.3.5.569","article-title":"Current concepts of metastasis in melanoma","volume":"3","year":"2008","journal-title":"Expert Rev Dermatol"},{"key":"bib4-20250802","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A landscape of driver mutations in melanoma","volume":"150","year":"2012","journal-title":"Cell"},{"key":"bib5-20250802","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","year":"2015","journal-title":"Cell"},{"key":"bib6-20250802","article-title":"Decoding the genomic report for radiologists","volume":"1\u201313","year":"2020","journal-title":"Am J Roentgenol"},{"key":"bib7-20250802","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"key":"bib8-20250802","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","year":"2018","journal-title":"Lancet Oncol"},{"key":"bib9-20250802","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","year":"2016","journal-title":"Lancet Oncol"},{"key":"bib10-20250802","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"key":"bib11-20250802","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","year":"2011","journal-title":"N Engl J Med"},{"key":"bib12-20250802","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","year":"2014","journal-title":"N Engl J Med"},{"key":"bib13-20250802","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","year":"2019","journal-title":"N Engl J Med"},{"key":"bib14-20250802","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","year":"2016","journal-title":"Lancet Oncol"},{"key":"bib15-20250802","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial","volume":"19","year":"2018","journal-title":"Lancet Oncol"},{"key":"bib16-20250802","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejca.2019.11.016","article-title":"Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma","volume":"126","year":"2020","journal-title":"Eur J Cancer"},{"key":"bib17-20250802","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1001\/jama.2011.746","article-title":"KIT as a therapeutic target in metastatic melanoma","volume":"305","year":"2011","journal-title":"JAMA"},{"key":"bib18-20250802","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1200\/JCO.2012.47.7836","article-title":"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin","volume":"31","year":"2013","journal-title":"J Clin Oncol"},{"key":"bib19-20250802","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1158\/1078-0432.CCR-14-1630","article-title":"Phase II study of nilotinib in melanoma harboring KIT alterations following progression to prior KIT inhibition","volume":"21","year":"2015","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"bib20-20250802","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/annonc\/mdx079","article-title":"Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial","volume":"28","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"bib21-20250802","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.annonc.2020.07.004","article-title":"ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO guidelines committee","volume":"31","year":"2020","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"bib22-20250802","doi-asserted-by":"crossref","first-page":"364","DOI":"10.6004\/jnccn.2021.0018","article-title":"NCCN guidelines\u00ae insights: melanoma: cutaneous, version 2.2021","volume":"19","year":"2021","journal-title":"J Natl Compr Cancer Netw J Natl Compr Canc Netw"},{"key":"bib23-20250802","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","article-title":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","volume":"395","year":"2020","journal-title":"Lancet (London, England)"},{"key":"bib24-20250802","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","year":"1981","journal-title":"Cancer"},{"key":"bib25-20250802","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","year":"2000","journal-title":"JNCI J Natl Cancer Inst"},{"key":"bib26-20250802","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","year":"2009","journal-title":"Eur J Cancer"},{"key":"bib27-20250802","doi-asserted-by":"crossref","first-page":"7412 LP","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","year":"2009","journal-title":"Clin Cancer Res"},{"key":"bib28-20250802","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1200\/JCO.2015.61.6870","article-title":"Pseudoprogression and immune-related response in solid tumors","volume":"33","year":"2015","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"bib29-20250802","doi-asserted-by":"crossref","first-page":"1920 LP","DOI":"10.1158\/1078-0432.CCR-16-1741","article-title":"Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti\u2013PD-1\/PD-L1","volume":"23","year":"2017","journal-title":"Clin Cancer Res"},{"key":"bib30-20250802","doi-asserted-by":"crossref","first-page":"e211136","DOI":"10.1001\/jamanetworkopen.2021.1136","article-title":"Definition, incidence, and challenges for assessment of hyperprogressive disease during cancer treatment with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","year":"2021","journal-title":"JAMA Netw Open"},{"key":"bib31-20250802","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ctrv.2018.07.006","article-title":"Hyperprogression as a distinct outcome after immunotherapy","volume":"70","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"bib32-20250802","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1158\/1078-0432.CCR-13-0895","article-title":"Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements","volume":"19","year":"2013","journal-title":"Clin cancer Res an Off J Am Assoc Cancer Res"},{"key":"bib33-20250802","doi-asserted-by":"crossref","first-page":"902","DOI":"10.2214\/AJR.11.7280","article-title":"PET\/CT in the management of patients with stage IIIC and IV metastatic melanoma considered candidates for surgery: evaluation of the additive value after conventional imaging","volume":"198","year":"2012","journal-title":"Am J Roentgenol"},{"key":"bib34-20250802","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","article-title":"Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations","volume":"35","year":"1999","journal-title":"Eur J Cancer"},{"key":"bib35-20250802","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors","volume":"50","year":"2009","journal-title":"J Nucl Med"},{"key":"bib36-20250802","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2967\/jnumed.116.188839","article-title":"Prediction of response to immune checkpoint inhibitor therapy using early-time-point (18)F-FDG PET\/CT imaging in patients with advanced melanoma","volume":"58","year":"2017","journal-title":"J Nucl Med"},{"key":"bib37-20250802","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s00330-020-07249-y","article-title":"Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial","volume":"31","year":"2021","journal-title":"Eur Radiol"},{"key":"bib38-20250802","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1148\/radiol.2020200443","article-title":"Incidence of pseudoprogression during immune checkpoint inhibitor therapy for solid tumors: a systematic review and meta-analysis","volume":"297","year":"2020","journal-title":"Radiology"},{"key":"bib39-20250802","article-title":"Comparison of RECIST 1.1 and iRECIST in patients treated with immune checkpoint inhibitors","volume":"13","year":"2021","journal-title":"System Rev Meta-Analysis Cancers (Basel)"},{"key":"bib40-20250802","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/jco.2015.33.15_suppl.3000","article-title":"Atypical patterns of response in patients (pts) with metastatic melanoma treated with pembrolizumab (MK-3475) in KEYNOTE-001","volume":"33","year":"2015","journal-title":"J Clin Oncol"},{"key":"bib41-20250802","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s00259-018-3972-9","article-title":"The role of interim (18)F-FDG PET\/CT in prediction of response to ipilimumab treatment in metastatic melanoma","volume":"45","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib42-20250802","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3904\/kjim.2017.063","article-title":"Comparison of the morphologic criteria (RECIST) and metabolic criteria (EORTC and PERCIST) in tumor response assessments: a pooled analysis","volume":"34","year":"2019","journal-title":"Korean J Intern Med"},{"key":"bib43-20250802","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/2326-6066.CIR-15-0102","article-title":"Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with Ipilimumab","volume":"3","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"bib44-20250802","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","year":"2018","journal-title":"JAMA Oncol"},{"key":"bib45-20250802","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"key":"bib46-20250802","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S0140-6736(20)30417-7","article-title":"Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"395","year":"2020","journal-title":"Lancet (London, England)"},{"key":"bib47-20250802","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/CMR.0000000000000541","article-title":"18F-FDG PET\/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab","volume":"29","year":"2019","journal-title":"Melanoma Res"},{"key":"bib48-20250802","article-title":"NCCN clinical practice guidelines in oncology. Management of immune checkpoint inhibitor toxicities, version 3.2021","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"bib49-20250802","first-page":"e1344805","article-title":"Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: a systematic review and meta-analysis","volume":"6","year":"2017","journal-title":"Onco Targets Ther"},{"key":"bib50-20250802","doi-asserted-by":"crossref","first-page":"W468","DOI":"10.2214\/AJR.12.9751","article-title":"Ipilimumab-associated colitis: CT findings","volume":"200","year":"2013","journal-title":"AJR Am J Roentgenol"},{"key":"bib51-20250802","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00261-015-0560-3","article-title":"Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis","volume":"41","year":"2016","journal-title":"Abdom Radiol (New York)"},{"key":"bib52-20250802","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis","volume":"2","year":"2016","journal-title":"JAMA Oncol"},{"key":"bib53-20250802","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1158\/1078-0432.CCR-16-1320","article-title":"PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course","volume":"22","year":"2016","journal-title":"Clin Cancer Res"},{"key":"bib54-20250802","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1200\/JCO.2016.72.1167","article-title":"Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma","volume":"35","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"bib55-20250802","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/2326-6066.CIR-16-0237","article-title":"Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1\/PD-L1 inhibitors in cancer patients","volume":"5","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"bib56-20250802","doi-asserted-by":"crossref","first-page":"e201611","DOI":"10.1001\/jamanetworkopen.2020.1611","article-title":"Immune checkpoint inhibitors and immune-related adverse events in patients with advanced melanoma: a systematic review and network meta-analysis","volume":"3","year":"2020","journal-title":"JAMA Netw Open"},{"key":"bib57-20250802","first-page":"1071","article-title":"Ipilimumab associated hepatitis: imaging and clinicopathologic findings","volume":"31"},{"key":"bib58-20250802","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","year":"2018","journal-title":"JAMA Oncol"},{"key":"bib59-20250802","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.clinimag.2017.12.014","article-title":"Multimodality imaging of endocrine immune related adverse events: a primer for radiologists","volume":"50","year":"2018","journal-title":"Clin Imaging"},{"key":"bib60-20250802","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.pan.2019.04.015","article-title":"Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: a systematic review and meta-analysis","volume":"19","year":"2019","journal-title":"Pancreatol Off J Int Assoc Pancreatol"},{"key":"bib61-20250802","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40425-019-0502-7","article-title":"Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury","volume":"7","year":"2019","journal-title":"J Immunother Cancer"},{"key":"bib62-20250802","doi-asserted-by":"crossref","first-page":"109250","DOI":"10.1016\/j.ejrad.2020.109250","article-title":"Imaging findings of immune checkpoint inhibitor associated pancreatitis","volume":"131","year":"2020","journal-title":"Eur J Radiol"},{"key":"bib63-20250802","doi-asserted-by":"crossref","first-page":"W992","DOI":"10.2214\/AJR.10.6198","article-title":"Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti\u2013CTLA-4 antibody therapy","volume":"197","year":"2011","journal-title":"Am J Roentgenol"},{"key":"bib64-20250802","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1158\/2326-6066.CIR-17-0715","article-title":"Sarcoid-like granulomatosis of the lung related to immune-checkpoint inhibitors: distinct clinical and imaging features of a unique immune-related adverse event","volume":"6","year":"2018","journal-title":"Cancer Immunol Res"}],"container-title":["Journal of Computer Assisted Tomography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RCT.0000000000001315","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T23:17:23Z","timestamp":1754176643000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RCT.0000000000001315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,4]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/rct.0000000000001315","relation":{},"ISSN":["1532-3145","0363-8715"],"issn-type":[{"value":"1532-3145","type":"electronic"},{"value":"0363-8715","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6,4]]}}}